FBLG
What one share of FibroBiologics holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid.
FibroBiologics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.77 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$3.89 |
| Cash and investments | $0.53 |
| Book value | $0.70 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$3.63 | — | −$2.88 | — | −$2.83 |
| 2023 | — | −$13.50 | $0.35 | −$4.89 | — | $0.77 |
| 2024 | — | −$6.79 | $0.11 | −$7.35 | — | $1.45 |
| 2025 | — | −$8.35 | $0.12 | −$7.46 | — | $1.82 |